Free Trial

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals logo
$7.72 -0.31 (-3.86%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.56 -0.16 (-2.07%)
As of 08/1/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Key Stats

Today's Range
$7.69
$8.08
50-Day Range
$4.72
$8.43
52-Week Range
$1.76
$8.72
Volume
1.84 million shs
Average Volume
1.45 million shs
Market Capitalization
$688.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.75
Consensus Rating
Buy

Company Overview

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

AMLX MarketRank™: 

Amylyx Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 509th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amylyx Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amylyx Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Amylyx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amylyx Pharmaceuticals is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amylyx Pharmaceuticals is -2.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amylyx Pharmaceuticals has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amylyx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.44% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently increased by 12.84%, indicating that investor sentiment is decreasing significantly.
  • Percentage of Shares Shorted

    11.44% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 5.2.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently increased by 12.84%, indicating that investor sentiment is decreasing significantly.
  • Search Interest

    Only 6 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amylyx Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amylyx Pharmaceuticals' insider trading history.
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMLX Stock News Headlines

Buffett to put 90% of his money in this one stock?
CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accounting firms like Deloitte and KPMG, Joel Litman (who’s also a member of the Global CFA Institute) figured out a unique, less-risky way to grow rich in the stock market. Litman says you don’t need dozens of investments, overpriced advisers, or hedge funds. You just need these 3 stocks, which have helped Litman’s own mom earn 3,400%.
See More Headlines

AMLX Stock Analysis - Frequently Asked Questions

Amylyx Pharmaceuticals' stock was trading at $3.78 at the beginning of 2025. Since then, AMLX stock has increased by 104.2% and is now trading at $7.72.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) issued its earnings results on Thursday, May, 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.03.
Read the conference call transcript
.

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering (IPO) on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

Top institutional shareholders of Amylyx Pharmaceuticals include Aberdeen Group plc (0.83%) and Y Intercept Hong Kong Ltd (0.27%). Insiders that own company stock include Morningside Venture Investment, Joshua B Cohen, Justin B Klee, Global Investors Lp Viking, George M Milne Jr, James M Frates, Patrick D Yeramian, Camille L Bedrosian, Gina Mazzariello, Bernhardt G Zeiher and Daphne Quimi.
View institutional ownership trends
.

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
5/08/2025
Today
8/02/2025
Next Earnings (Confirmed)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMLX
CIK
1658551
Fax
N/A
Employees
200
Year Founded
N/A

Price Target and Rating

High Price Target
$17.00
Low Price Target
$8.00
Potential Upside/Downside
+52.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
13 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$301.74 million
Net Margins
N/A
Pretax Margin
-345.81%
Return on Equity
-77.21%
Return on Assets
-63.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.05
Quick Ratio
12.05

Sales & Book Value

Annual Sales
-$1.27 million
Price / Sales
-541.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
3.22

Miscellaneous

Outstanding Shares
89,141,000
Free Float
78,712,000
Market Cap
$688.17 million
Optionable
Optionable
Beta
-0.49

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:AMLX) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners